Since tumor cells may exploit complement regulatory proteins to prevent CDC, which might impact the efficacy of monoclonal antibodies employing CDC as part of their antitumor effect, we next examined the expression of the complement inhibitors CD46, CD55, and CD59 on the surface of MM and DLBCL cells. The gene discussed is CD46; the disease is neoplasm.